Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00681746 | Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280 | PHASE1 | COMPLETED | 8 | — | — | Feb 1, 2008 | Sep 1, 2008 | Dec 10, 2010 | 1 | Sweden |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AZD6280 | DRUG | Single dose of oral solution or capsule(s). 3 times for the 2 subjects in Panel 1. Once for the 6 remaining subjects. |
| (11C) flumazenil | DRUG | Single dose of intravenous solution. 4 times for 2 subjects in Panel 1. 2 times for the remaining 6 subjects. (once together with AZD6280) |
Inclusion Criteria: * Body Mass Index (BMI) of 18-30 kg/m2 and weight of 60-100 kg * Clinically normal physical findings, medical history and laboratory values. Exclusion Criteria: * Clinically significant illness or clinical relevant trauma within 2 weeks before the study start. * History of cli...